Optimizing the treatment of haemophilia B: Laboratory and clinical perspectives

Louis M. Aledort

doi:10.1111/j.1365-2516.2010.02298.x

Optimizing the treatment of haemophilia B: Laboratory and clinical perspectives

Louis M. Aledort

Research output: Contribution to journal › Editorial

3 Scopus citations

Abstract

Hemophilia A and B are traditionally thought of as a single bleeding disorder, viewed as opposite sides of the same coin. Yet the differences between the 2 forms of congenital hemophilia extend far beyond the type of deficient clotting factor-factor VIII for hemophilia A and factor IX (FIX) for hemophilia B. This supplement focuses on the unique laboratory and clinical issues associated with FIX replacement therapy for children and adults with hemophilia B.

Original language	English
Pages (from-to)	1-2
Number of pages	2
Journal	Haemophilia
Volume	16
Issue number	SUPPL. 6
DOIs	https://doi.org/10.1111/j.1365-2516.2010.02298.x
State	Published - Jul 2010

Keywords

Chromogenic assays
Clotting assays
Factor IX
Haemophilia B
Pharmacokinetics
Prophylaxis

Access to Document

10.1111/j.1365-2516.2010.02298.x

Cite this

@article{b4edb2087a0f422fa82c78201f06b305,

title = "Optimizing the treatment of haemophilia B: Laboratory and clinical perspectives",

abstract = "Hemophilia A and B are traditionally thought of as a single bleeding disorder, viewed as opposite sides of the same coin. Yet the differences between the 2 forms of congenital hemophilia extend far beyond the type of deficient clotting factor-factor VIII for hemophilia A and factor IX (FIX) for hemophilia B. This supplement focuses on the unique laboratory and clinical issues associated with FIX replacement therapy for children and adults with hemophilia B.",

keywords = "Chromogenic assays, Clotting assays, Factor IX, Haemophilia B, Pharmacokinetics, Prophylaxis",

author = "Aledort, {Louis M.}",

year = "2010",

month = jul,

doi = "10.1111/j.1365-2516.2010.02298.x",

language = "English",

volume = "16",

pages = "1--2",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "John Wiley and Sons Inc.",

number = "SUPPL. 6",

}

TY - JOUR

T1 - Optimizing the treatment of haemophilia B

T2 - Laboratory and clinical perspectives

AU - Aledort, Louis M.

PY - 2010/7

Y1 - 2010/7

N2 - Hemophilia A and B are traditionally thought of as a single bleeding disorder, viewed as opposite sides of the same coin. Yet the differences between the 2 forms of congenital hemophilia extend far beyond the type of deficient clotting factor-factor VIII for hemophilia A and factor IX (FIX) for hemophilia B. This supplement focuses on the unique laboratory and clinical issues associated with FIX replacement therapy for children and adults with hemophilia B.

AB - Hemophilia A and B are traditionally thought of as a single bleeding disorder, viewed as opposite sides of the same coin. Yet the differences between the 2 forms of congenital hemophilia extend far beyond the type of deficient clotting factor-factor VIII for hemophilia A and factor IX (FIX) for hemophilia B. This supplement focuses on the unique laboratory and clinical issues associated with FIX replacement therapy for children and adults with hemophilia B.

KW - Chromogenic assays

KW - Clotting assays

KW - Factor IX

KW - Haemophilia B

KW - Pharmacokinetics

KW - Prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=77954648162&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2010.02298.x

DO - 10.1111/j.1365-2516.2010.02298.x

M3 - Editorial

C2 - 20561350

AN - SCOPUS:77954648162

SN - 1351-8216

VL - 16

SP - 1

EP - 2

JO - Haemophilia

JF - Haemophilia

IS - SUPPL. 6

ER -

Optimizing the treatment of haemophilia B: Laboratory and clinical perspectives

Abstract

Keywords

Access to Document

Fingerprint

Cite this